Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer (2024)

Peer-Reviewed Study · Li Z; Li N; Ndzie Noah ML; Shao Q; Zhan X; et al. · December 2024

Li Z et al., 2024-12: Mouse ovarian cancer (TOV-21G) study with proteomic analysis reporting 61.5% tumour inhibition at 10 mg/kg ivermectin and identifying energy metabolism pathways as the drug's target.

Ivermectin (10 mg/kg) had a significant anti-ovarian cancer effect in mice, with a tumor inhibitory rate of 61.5%.

n/a (HTML full text)

Li Z et al., 2024-12: Mouse ovarian cancer (TOV-21G) study with proteomic analysis reporting 61.5% tumour inhibition at 10 mg/kg ivermectin and identifying energy metabolism pathways as the drug's target. Study type: mouse xenograft (TOV-21G) plus TMT proteomics. N: not stated in the abstract. Country: China (Shandong Cancer Hospital, Jinan). Dose: 10 mg/kg (route and schedule not stated in the abstract). Declared COI: 'The authors declare no competing interests.' Comparator: vehicle-treated tumour-bearing mice. Extends the mitochondrial/energy-metabolism arm to ovarian cancer in vivo. Study type: animal.